HK1043388A1 - Modified chimeric polypeptides with improved pharmacokinetic properties. - Google Patents

Modified chimeric polypeptides with improved pharmacokinetic properties.

Info

Publication number
HK1043388A1
HK1043388A1 HK02105009A HK02105009A HK1043388A1 HK 1043388 A1 HK1043388 A1 HK 1043388A1 HK 02105009 A HK02105009 A HK 02105009A HK 02105009 A HK02105009 A HK 02105009A HK 1043388 A1 HK1043388 A1 HK 1043388A1
Authority
HK
Hong Kong
Prior art keywords
chimeric polypeptides
pharmacokinetic properties
modified chimeric
improved pharmacokinetic
modified
Prior art date
Application number
HK02105009A
Other languages
English (en)
Inventor
Nicholas J Papadopoulos
Samuel Davis
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1043388(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1043388A1 publication Critical patent/HK1043388A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
HK02105009A 1999-06-08 2002-07-04 Modified chimeric polypeptides with improved pharmacokinetic properties. HK1043388A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08
PCT/US2000/014142 WO2000075319A1 (en) 1999-06-08 2000-05-23 Modified chimeric polypeptides with improved pharmacokinetic properties

Publications (1)

Publication Number Publication Date
HK1043388A1 true HK1043388A1 (en) 2002-09-13

Family

ID=22480568

Family Applications (3)

Application Number Title Priority Date Filing Date
HK02105009A HK1043388A1 (en) 1999-06-08 2002-07-04 Modified chimeric polypeptides with improved pharmacokinetic properties.
HK09110323.8A HK1132653A1 (en) 1999-06-08 2009-11-05 Modified chimeric polypeptides with improved pharmacokinetic properties
HK13113191.5A HK1185798A1 (en) 1999-06-08 2013-11-26 Modified chimeric polypeptides with improved pharmacokinetic properties

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK09110323.8A HK1132653A1 (en) 1999-06-08 2009-11-05 Modified chimeric polypeptides with improved pharmacokinetic properties
HK13113191.5A HK1185798A1 (en) 1999-06-08 2013-11-26 Modified chimeric polypeptides with improved pharmacokinetic properties

Country Status (33)

Country Link
EP (2) EP1183353B1 (pt)
JP (2) JP4723140B2 (pt)
KR (1) KR100659477B1 (pt)
CN (3) CN100523187C (pt)
AT (2) ATE293164T1 (pt)
AU (2) AU779303B2 (pt)
BE (1) BE2013C029I2 (pt)
BR (2) BRPI0011407B8 (pt)
CA (1) CA2376379C (pt)
CY (2) CY1108883T1 (pt)
CZ (2) CZ303656B6 (pt)
DE (2) DE60019415T2 (pt)
DK (2) DK1183353T3 (pt)
ES (2) ES2237429T3 (pt)
FR (1) FR13C0028I2 (pt)
HK (3) HK1043388A1 (pt)
HR (1) HRP20010908B1 (pt)
HU (3) HU230159B1 (pt)
IL (3) IL146890A0 (pt)
LT (1) LTC1183353I2 (pt)
LU (1) LU92195I2 (pt)
ME (2) ME00024B (pt)
MX (1) MXPA01012630A (pt)
NO (3) NO330775B1 (pt)
NZ (1) NZ515913A (pt)
PL (1) PL208247B1 (pt)
PT (2) PT1544299E (pt)
RS (1) RS50073B (pt)
RU (1) RU2265661C2 (pt)
SK (1) SK287332B6 (pt)
UA (1) UA74146C2 (pt)
WO (1) WO2000075319A1 (pt)
ZA (1) ZA200110068B (pt)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ATE359300T1 (de) 2001-01-19 2007-05-15 Ludwig Inst Cancer Res Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
EP1575548B1 (en) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
WO2004087206A2 (en) * 2003-03-28 2004-10-14 Regeneron Pharmaceuticals, Inc. Methods of treating diabetes by blocking vegf-mediated activity
JP5399612B2 (ja) * 2003-05-16 2014-01-29 アコーダ セラピューティクス、インク． Ｃｎｓを治療するための融合タンパク質
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MXPA05012307A (es) 2003-05-16 2006-07-03 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
WO2004106378A2 (en) * 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
WO2004110490A2 (en) * 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
CA2534197A1 (en) * 2003-08-06 2005-02-24 Thomas Jefferson University Use of a vegf antagonist in combination with radiation therapy
AU2005244933B2 (en) 2004-05-18 2011-08-04 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
WO2005121176A1 (fr) * 2004-06-08 2005-12-22 Chengdu Kanghong Biotechnologies Co. Ltd Proteine chimerique inhibitrice d'angiogenese et utilisation associee
WO2005123104A2 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
CN1968709A (zh) * 2004-06-18 2007-05-23 瑞泽恩制药公司 用于治疗恶性胸腔积液的vegf抑制剂
JP4807802B2 (ja) * 2004-07-30 2011-11-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆ媒介性活性をブロックすることによるｉ型糖尿病を処置する方法
ES2347340T3 (es) 2004-09-13 2010-10-28 Genzyme Corporation Construcciones multimericas.
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
WO2006088650A2 (en) * 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
LT2586459T (lt) 2005-03-25 2017-09-25 Regeneron Pharmaceuticals, Inc. Vegf antagonisto kompozicijos
EP1928490B8 (en) 2005-09-26 2012-10-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
CA2630839C (en) † 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
LT2944306T (lt) 2006-06-16 2021-02-25 Regeneron Pharmaceuticals, Inc. Vfgf antagonisto kompozicijos, tinkamos įvedimui intravitrealiniu būdu
PL2066694T3 (pl) 2006-09-29 2016-04-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
EP2358746B1 (en) 2008-11-03 2020-09-16 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
PL3072526T3 (pl) 2009-10-16 2019-04-30 Oncomed Pharm Inc Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem DLL4 i środków antyhipertensyjnych
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
SI2601214T1 (en) 2010-08-06 2018-03-30 Genzyme Corporation VEGF antagonist compositions and their use
EP3539991A1 (en) * 2011-01-07 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
KR20200077622A (ko) 2011-01-13 2020-06-30 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
HUE046134T2 (hu) 2012-05-07 2020-02-28 Allergan Inc Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
TW201438736A (zh) 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
US9745558B2 (en) 2013-02-18 2017-08-29 Vegenics Pty Limited VEGFR-3 ligand binding molecules and uses thereof
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
ES2773317T3 (es) 2013-11-05 2020-07-10 Allergan Inc Método de tratamiento de estados del ojo con un DARPin anti-VEGF
EP3492495A1 (en) 2014-05-12 2019-06-05 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
KR102486321B1 (ko) 2014-07-18 2023-01-09 사노피 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
CN112826934A (zh) 2014-12-11 2021-05-25 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
WO2017065559A1 (ko) 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
US20180326126A1 (en) 2015-11-18 2018-11-15 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
EP3377100A1 (en) 2015-11-18 2018-09-26 Formycon AG Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
RU2751510C2 (ru) 2015-11-18 2021-07-14 Сио2 Медикал Продактс, Инк. Фармацевтическая упаковка для офтальмологических составов
CN108697792A (zh) * 2015-11-19 2018-10-23 珠海泰瑞尚生物医药科技有限公司 用于结合vegf的方法和组合物
FI3384049T3 (fi) 2015-12-03 2023-09-25 Regeneron Pharma Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
JPWO2018070390A1 (ja) 2016-10-12 2019-08-22 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
WO2018094316A1 (en) 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
EP3630062A2 (en) 2017-05-24 2020-04-08 SiO2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
DK3668985T3 (da) 2017-08-17 2021-09-20 Just Evotec Biologics Inc Fremgangsmåde til rensning af glycosyleret protein fra værtscellegalectiner og andre urenheder
WO2019099965A1 (en) 2017-11-20 2019-05-23 Just Biotherapeutics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
FI3717636T3 (fi) 2017-11-27 2023-06-01 4D Molecular Therapeutics Inc Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä
MX2020005166A (es) 2017-11-30 2020-09-03 Regeneron Pharma Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos.
IL275125B2 (en) 2017-12-13 2023-12-01 Regeneron Pharma Apparatus and methods for support management of chromatography column substrate and related methods
SG11202007130RA (en) * 2018-01-26 2020-08-28 Univ California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
US20220204920A1 (en) 2019-05-16 2022-06-30 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
AU2020343242A1 (en) 2019-09-03 2022-03-10 Amgen Inc. Injection device for drug delivery and packaging for the injection device
WO2021056020A1 (en) 2019-09-16 2021-03-25 Amgen Inc. Method for external sterilization of drug delivery device
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization
BR112021025769A2 (pt) 2019-12-06 2022-04-12 Regeneron Pharma Composições de proteína anti-vegf e métodos para a produção das mesmas
BR112022010686A2 (pt) 2019-12-06 2022-08-23 Regeneron Pharma Mini-traps de vegf e métodos de uso dos mesmos
CA3167020A1 (en) 2020-02-24 2021-09-02 Amgen Inc. Containers and systems for use during external sterilization of drug delivery devices
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
KR20240019034A (ko) * 2022-08-02 2024-02-14 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
CY1108883T1 (el) 2014-07-02
EP1183353A1 (en) 2002-03-06
IL190234A0 (en) 2008-11-03
JP2011024595A (ja) 2011-02-10
AU2005201365B2 (en) 2007-08-09
NO20100656L (no) 2002-02-08
PL352246A1 (en) 2003-08-11
RS50073B (sr) 2009-01-22
BR0011407A (pt) 2002-04-02
FR13C0028I1 (fr) 2013-06-14
FR13C0028I2 (fr) 2014-05-16
MEP3208A (xx) 2010-02-10
HUP0201515A3 (en) 2004-12-28
JP5273746B2 (ja) 2013-08-28
CZ303656B6 (cs) 2013-01-30
ES2319305T3 (es) 2009-05-06
CN101433715B (zh) 2013-04-17
HUP0201515A2 (en) 2002-08-28
HU230159B1 (hu) 2015-09-28
PT1183353E (pt) 2005-06-30
LU92195I2 (fr) 2013-07-15
JP2003501089A (ja) 2003-01-14
NO332559B1 (no) 2012-10-29
CN103349781A (zh) 2013-10-16
CZ20014387A3 (cs) 2002-10-16
AU2005201365A1 (en) 2005-04-28
AU779303B2 (en) 2005-01-13
CA2376379A1 (en) 2000-12-14
IL146890A (en) 2008-07-08
NZ515913A (en) 2004-01-30
LTPA2013009I1 (lt) 2013-06-25
RU2265661C2 (ru) 2005-12-10
EP1183353B1 (en) 2005-04-13
BRPI0011407B1 (pt) 2018-09-25
AU5040400A (en) 2000-12-28
ATE293164T1 (de) 2005-04-15
ZA200110068B (en) 2002-12-06
NO2013010I1 (no) 2013-06-17
NO330775B1 (no) 2011-07-11
BRPI0011407B8 (pt) 2021-05-25
CN100523187C (zh) 2009-08-05
KR100659477B1 (ko) 2006-12-20
HK1132653A1 (en) 2010-03-05
DE60041159D1 (de) 2009-01-29
KR20020019070A (ko) 2002-03-09
DK1183353T3 (da) 2005-08-08
CZ302689B6 (cs) 2011-09-07
YU86901A (sh) 2004-05-12
EP1544299A1 (en) 2005-06-22
NO20016036D0 (no) 2001-12-10
NO2013010I2 (no) 2013-05-15
HK1185798A1 (en) 2014-02-28
PL208247B1 (pl) 2011-04-29
CY2013019I2 (el) 2015-11-04
BE2013C029I2 (pt) 2019-03-06
JP4723140B2 (ja) 2011-07-13
PT1544299E (pt) 2009-03-18
HUS1300052I1 (hu) 2016-08-29
NO20016036L (no) 2002-02-08
MXPA01012630A (es) 2002-07-22
LTC1183353I2 (lt) 2023-02-27
IL146890A0 (en) 2002-08-14
CN1369009A (zh) 2002-09-11
CN101433715A (zh) 2009-05-20
WO2000075319A1 (en) 2000-12-14
DE60019415T2 (de) 2006-03-09
ATE417928T1 (de) 2009-01-15
UA74146C2 (uk) 2005-11-15
CY2013019I1 (el) 2015-11-04
DK1544299T3 (da) 2009-03-23
ES2237429T3 (es) 2005-08-01
ME00024B (me) 2010-02-10
HRP20010908A2 (en) 2005-04-30
CN103349781B (zh) 2015-04-01
SK17522001A3 (sk) 2003-04-01
DE60019415D1 (de) 2005-05-19
EP1544299B1 (en) 2008-12-17
HRP20010908B1 (en) 2006-05-31
SK287332B6 (sk) 2010-07-07
HU229156B1 (en) 2013-09-30
CA2376379C (en) 2007-08-07

Similar Documents

Publication Publication Date Title
HK1185798A1 (en) Modified chimeric polypeptides with improved pharmacokinetic properties
IL146082A0 (en) Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
DE60137876D1 (de) Analoge des Glucagon-ähnlichen Peptids-1
EP2135617A3 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
PT1326630E (pt) Utilização de péptidos glp-2
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
HK1050495A1 (en) Device for reconstituting a therapeutic solution, suspension or dispersion.
PT1181319E (pt) Anticorpos quiméricos contra dr4 e suas utilizações
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
AU5977501A (en) Method for treating retinal degeneration with purinergic receptor agonists
IL145584A0 (en) Nmda nr2b antagonists for treatment
AU4687101A (en) Fine carbon fiber and process for producing the same, and conductive material comprising the same
AU754616C (en) N-(phenylsulfonyl) picolinamide derivatives, process for producing the same, and herbicide
ZA200309642B (en) Benzo (G) quinoline derivatives for treating glaucoma and myopia.
WO2005058911A3 (en) Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
WO2003028651A3 (en) Antipsychotic agents stimulate neurogenesis in brain
ZA200203589B (en) Concomitant drugs for treating glaucoma.
AU2002247731A1 (en) Pigmentary epithelium cell of the eye, the production thereof and the use of the same for treating diseases of the eye or of the central nervous system

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20200522